Image
boardroom hero
Advertisement
08/10/2022

Amneal appoints Deborah Autor to board of directors

Autor has biopharmaceutical industry expertise in quality, regulatory and policy.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Amneal is welcoming Deborah Autor to the company’s board of directors, effective July 29, 2022, bringing the number of board directors to 11.

Deb brings decades of global public and private expertise in the biopharmaceutical sector to our board at an important time of growth for Amneal, Chirag and Chintu Patel, Amneal co-CEOs said.

She has a proven track record of service and impact throughout her distinguished career in quality, regulatory and policy,” they said.“We are delighted to welcome Deb to the board and look forward to working closely with her as we execute our strategy and expand our business into new and more complex high growth areas.

[Read more: Amneal debuts 2 generics]

Most recently, Autor had global quality and regulatory leadership roles at AstraZeneca and Mylan N.V. From 2019 to 2021, she was global head of regulatory excellence at AstraZeneca, where she led regulatory operations, policy and intelligence for its submissions.

Autor was at Mylan N.V. from 2013 to 2019, where she was head of strategic global quality and regulatory policy. Prior to her leadership within the industry, she served at the Food and Drug Administration for over a decade, including as deputy commissioner for global regulatory operations and policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco, and food.

Before that, Autor served as director of the Office of Compliance at the Center for Drug Evaluation and Research, leading enforcement and policymaking for compliance with all drug requirements, including, drug approval, current good manufacturing practices, human subject protection and bioresearch monitoring, import and export, and recalls.

[Read more: Amneal receives FDA blessing for 4 generics

Before joining the FDA, Autor was a trial attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of the FDA. During her time at the FDA, she won several public service awards.

She received her law degree from Boston University School of Law, where she graduated magna cum laude, and her bachelors degree in psychology from Columbia University, Barnard College. Autor also has diverse board experience, including currently serving as a board director at Pardes Biosciences and chair of the board for the FDA Alumni Association.

    Advertisement
    Advertisement